According to two reports from Israel, the incidence of myocarditis following the administration of the Pfizer-BioNTech COVID vaccine appeared to be several-fold higher in comparison with some estimates; however, it continued to be low over late spring this year.

Among patients in Clalit Health Services, the country’s largest healthcare system, the estimate of myocarditis was 2.13 cases per 100,000 vaccinated individuals, with as high as 10.69 cases per 100,000 among men and boys in the 16 to 29 years age bracket.

In another study that used Israel′s government database, the findings supported a higher risk in young men. The estimate of myocarditis for males of all ages was 0.64 cases per 100,000 individuals following the first dose and 3.83 cases per 100,000 following the second shot. The incidence increased to 1.34 and 15.07 per 100,000 individuals following the first and second shot, respectively, for boys aged between 16 and 19 years. The studies were published online in the New England Journal of Medicine… (Medpage Today)